CNSY on Nasdaq

Plus Therapeutics

Logo: plustherapeutics.com3

Biopharmaceutical company.1

Price unavailable

Last updated Oct 19, 2026.

Overview

1996Founded1

Compare with Picard Medical, Inc., Lucid Diagnostics Inc. or INTELLIGENT BIO SOLUTIONS INC., or pick any stock.

  • TickerCNSY on Nasdaq1
  • IndustrySurgical & Medical Instruments & Apparatus1
  • HeadquartersAustin1
  • Websiteplustherapeutics.com
  • Incorporated inDE4
  • Business address6420 Levit Green Boulevard, Suite 310, Houston, Tx 770214
  • Filer categoryNon-accelerated filer, Smaller reporting company4
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Plus Therapeutics image from its website
Image: plustherapeutics.com3

Plus Therapeutics is a U.S. healthcare company developing and commercializing precision diagnostics and targeted radiopharmaceuticals for central nervous system (“CNS”) cancers. CNSide Diagnostics, LLC (“CNSide Diagnostics”) is our wholly owned subsidiary that develops and commercializes proprietary laboratory-developed tests, such as CNSide®, designed to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. In radiopharmaceuticals, our lead candidate, rhenium ( 186 Re) obisbemeda, is designed specifically for CNS cancers including recurrent glioblastoma (“GBM”), leptomeningeal metastases (“LM”), and pediatric brain cancers (“PBC”) by direct localized delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery (“CED”) and intraventricular brain (Ommaya reservoir) catheters. Our acquire…5 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-293.5%Operating margin6
-429.4%Net margin6
-10.5%Revenue growth, 20256
-560.2%Return on equity6
-$20.8MFree cash flow6

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Research and development100¢$8.4M

Out of $5.2M in revenue.6 The company lost money this year.

Financial statements

Revenue76$5.2M in 2025+6% since 2023
0$2.0M$4.0M$6.0M2023: $4.9M$4.9M20232024: $5.8M$5.8M2024+19%2025: $5.2M$5.2M2025−10%
Operating income89101176-$15.3M in 2025+318% since 2019
-$20.0M-$15.0M-$10.0M-$5.0M02019: -$3.7M-$3.7M20192020: -$9.6M-$9.6M2020+162%2021: -$12.5M-$12.5M2021+30%2022: -$19.7M-$19.7M2022+58%2023: -$13.3M-$13.3M2023−32%2024: -$14.7M-$14.7M2024+10%2025: -$15.3M-$15.3M2025+4%
Net income89101176-$22.4M in 2025+106% since 2019
-$30.0M-$20.0M-$10.0M02019: -$10.9M-$10.9M20192020: -$8.2M-$8.2M2020−24%2021: -$13.4M-$13.4M2021+63%2022: -$20.3M-$20.3M2022+51%2023: -$13.3M-$13.3M2023−34%2024: -$13.0M-$13.0M2024−3%2025: -$22.4M-$22.4M2025+72%

Every line of the income statement as filed: the last 2 fiscal years, latest first.6

Period ending2025-12-312024-12-31
Revenue$5.2M$5.8M
Research and development$8.4M$10.6M
General and administrative$12.1M$9.9M
Total operating expenses$20.5M$20.5M
Operating loss-$15.3M-$14.7M
Financing expense-$3.1M-$3.5M
Change in fair value of derivative instruments-$2.6M$5.7M
Warrant issuance costs-$964.0K-$486.0K
Interest income$116.0K$273.0K
Interest expense-$548.0K-$179.0K
Total other income (expense)-$7.1M$1.7M
Net loss-$22.4M-$13.0M
Net loss per share of common stock - basic-$0.29-$1.95
Net loss per share of common stock - diluted-$0.29-$2.34
Weighted average number of shares of common stock outstanding - basic77.8M shares6.6M shares
Weighted average number of shares of common stock outstanding - diluted77.8M shares7.7M shares

Compare Plus Therapeutics with another company

Leadership

Who has led Plus Therapeutics, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Christopher J. Calhoun2006–2014
  2. Marc H. Hedrick2014–now

President

  1. Marc H. Hedrick2006–2018
  2. Norio Seijiro Shirahama2007–2015

Chief financial officer

  1. Mark E. Saad2006–2014
  2. Tiago Girao2014–2018
200020052010201520202025
Board members and other officers (32)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Chief Financial OfficerAndrew H. Sims named Sep 18, 202653
  • DirectorAn H. van Es-Johansson named Sep 18, 202653

Former names

  • PLUS THERAPEUTICS, INC.Feb 8, 2019 to Jul 1, 20264
  • CYTORI THERAPEUTICS, INC.May 26, 2005 to Aug 2, 20194
  • MACROPORE INCJul 16, 2001 to Jul 5, 20054

Timeline

  1. Apr 15, 2014New chief executive Marc H. Hedrick becomes CEO15
  2. Jan 26, 2006New chief executive Christopher J. Calhoun becomes CEO16
  3. 2000Went public Listed on NASDAQ1
  4. 1996Founded Founded1

Filings

319 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 79 major events, 110 insider forms, 14 large holders, 1 private raises, 94 other. The latest 20:

  1. Oct 2, 20268-K EDGAR
  2. Oct 1, 20264 EDGAR
  3. Oct 1, 20264 EDGAR
  4. Oct 1, 20264 EDGAR
  5. Oct 1, 20264 EDGAR
  6. Oct 1, 20264 EDGAR
  7. Oct 1, 20264 EDGAR
  8. Oct 1, 20264 EDGAR
  9. Sep 18, 2026D EDGAR
  10. Sep 10, 20268-K EDGAR
  11. Aug 14, 202610-Q EDGAR
  12. Aug 14, 20268-K EDGAR
  13. Aug 4, 20268-K EDGAR
  14. Jul 1, 20264 EDGAR
  15. Jul 1, 20264 EDGAR
  16. Jul 1, 20264 EDGAR
  17. Jul 1, 20264 EDGAR
  18. Jul 1, 20264 EDGAR
  19. Jul 1, 20264 EDGAR
  20. Jul 1, 20264 EDGAR

The 319 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

40 open-market trades by officers, directors and large owners since October 2021: 38 buys and 2 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Nov 4, 2025Sims Andrew John Hugh MacIntyreChief Financial OfficerBuy20,000$0.51$10.2KForm 4
Aug 22, 2025Lenk Robert PDirectorBuy110,000$0.49$53.9KForm 4
Sep 13, 2024Hawkins Richard JDirectorBuy4,000$1.50$6.0KForm 4
Sep 12, 2024Hawkins Richard JDirectorBuy6,285$1.35$8.5KForm 4
Sep 11, 2024Petersen GregDirectorBuy12,500$1.35$16.9KForm 4
Sep 11, 2024Clowes HowardDirectorBuy5,000$1.34$6.7KForm 4
Sep 10, 2024HEDRICK MARC HChief Executive OfficerBuy8,000$1.23$9.8KForm 4
Sep 10, 2024Sims Andrew John Hugh MacIntyreChief Financial OfficerBuy4,098$1.27$5.2KForm 4
May 8, 2024Sims Andrew John Hugh MacIntyreChief Financial OfficerBuy4,902$2.04$10.0KForm 4
May 8, 2024HEDRICK MARC HChief Executive OfficerBuy12,255$2.04$25.0KForm 4
May 8, 2024Petersen GregDirectorBuy12,255$2.04$25.0KForm 4
May 8, 2024Hawkins Richard JDirectorBuy4,902$2.04$10.0KForm 4
May 8, 2024Clowes HowardDirectorBuy9,804$2.04$20.0KForm 4
May 8, 2024Lenk Robert PDirectorBuy4,167$2.04$8.5KForm 4
Nov 20, 2023HEDRICK MARC HChief Executive OfficerSale2,068$1.96$4.1KForm 4
Nov 16, 2023Lenk Robert PDirectorBuy1,000$1.95$1.9KForm 4
Nov 15, 2023Lenk Robert PDirectorBuy1,000$1.77$1.8KForm 4
Nov 13, 2023Lenk Robert PDirectorBuy4,000$1.43$5.7KForm 4
Nov 10, 2023Lenk Robert PDirectorBuy2,000$1.45$2.9KForm 4
Nov 9, 2023Lenk Robert PDirectorBuy4,199$1.59$6.7KForm 4

All 40 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Sep 10, 2026Raised $3 million in a private offering of securities Form D: $20 million offered in all Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Vanguard Capital Management LLC304,745$1.3M0.0%New
BlackRock, Inc.95,983$419.4K0.0%New
Geode Capital Management, LLC76,155$332.9K0.0%New
Vanguard Fiduciary Trust Co36,868$161.1K0.0%New
Ashton Thomas Private Wealth, LLC34,306$149.9K0.0%New
Citadel Advisors LLC25,597$111.9K0.0%New
Northern Trust Corp15,516$67.8K0.0%New
Wells Fargo & Company/mn6,156$26.9K0.0%New
Vanguard Global Advisers, LLC2,282$10.0K0.0%New
Osaic Holdings, Inc.2,000$8.7K0.0%New
Tower Research Capital LLC (TRC)1,955$8.5K0.0%New
UBS Group AG470$2.1K0.0%New
Allied Private Wealth LLC496$1.9K0.0%New
SBI Securities Co., Ltd.251$1.1K0.0%−2,393
Morgan Stanley185$8080.0%New
Barclays PLC96$4200.0%New
Citigroup Inc17$740.0%New
Virtu Financial LLC15,343$670.0%New
Caitong International Asset Management Co., Ltd12$520.0%New
Hrt Financial LP11,612$500.0%New
Global Retirement Partners, LLC4$170.0%New

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
    Company websitePlus Therapeutics logo
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61